MDWD (MediWound) Total Payout Ratio: 0.00 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDWD MediWound Ltd MDWD
56 GF Score
Price $14.16
GF Value $12.61
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is MediWound Total Payout Ratio?

MediWound MDWD -0.77% 56 Total Payout Ratio is 0.00 as of Jul. 16, 2026. GuruFocus rates MDWD with a GF Score™ of 56/100 and a GF Value™ of $12.61 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

MediWound's current Total Payout Ratio is 0.00.

MediWound Total Payout Ratio Related Terms

MediWound Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for MediWound's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MediWound Total Payout Ratio Chart

MediWound Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 1.96 3.71 0.73 1.15

MediWound Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MDWD vs UNCY, ARCT, NGEN: Total Payout Ratio Comparison

For the Biotechnology subindustry, MediWound's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MediWound Total Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MediWound's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where MediWound's Total Payout Ratio falls into.


MDWD
56GF Score
MediWound Ltd MDWD
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MediWound Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

MediWound's Total Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 27.416 + 0) / -23.879
=1.15

MediWound's Total Payout Ratio for the quarter that ended in Mar. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -2.952
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Ratio →
What does a Total Payout Ratio of 0.00 mean?
MediWound (MDWD) has a Total Payout Ratio of 0.00 as of Jul. 16, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on MediWound and its competitors.
Is MediWound's Total Payout Ratio too high?
MediWound's current Total Payout Ratio is 0.00. Overall, MediWound has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediWound's Total Payout Ratio compare to UNCY and ARCT?
MediWound's Total Payout Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Biotechnology company?
A good Total Payout Ratio depends on the Biotechnology industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on MediWound and its competitors. MediWound's current Total Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediWound stock overvalued right now?
Based on GuruFocus' analysis, MediWound (MDWD) is currently considered Modestly Overvalued. The stock's GF Value™ is $12.61, compared to a current price of $14.16 — trading 12.3% above its estimated fair value. The current Total Payout Ratio is 0.00. MediWound's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For MediWound (MDWD), the current Total Payout Ratio is 0.00 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MediWound (MDWD) Overvalued in 2026?

Based on GuruFocus' analysis, MediWound stock appears to be overvalued. The current stock price of $14.16 is trading 12.3% above its estimated GF Value™ of $12.61. GuruFocus considers MediWound to be Modestly Overvalued.

Key valuation signals for MDWD:

  • Total Payout Ratio: 0.00
  • GF Value™: $12.61 vs. price of $14.16 (12.3% above fair value)
  • GF Score™: 56/100 with 7 warning signs

No single metric tells the full story. See the MDWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MediWound Business Description

Other Exchanges M8W:Germany
Address 42 Hayarkon Street, Yavne, ISR, 8122745
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
56GF Score

Get the complete analysis for MDWD

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.16
Price
$12.61
GF Value